As clinical success, innovation, and investment in cell and gene therapy grows, emerging therapies are targeting more chronic conditions and cancers, in addition to rare diseases. This makes viral vector manufacturing — a critical component in gene and cell therapy — in demand. As more biopharma innovators focus on developing new therapies, many are choosing to partner with a CDMO that can support them from preclinical through commercialization.
Join our viral vector experts to learn more about our capabilities and solutions for gene therapy production as they highlight key features of our technologies and infrastructure through a virtual tour of the GMP manufacturing facility.
In this webinar, you will:
- Hear from our team of viral vector experts about our capabilities and solutions
- Discover how we support your gene therapy from preclinical to commercial production in a single facility
- Take a virtual tour of our state-of-the-art GMP manufacturing facility
Speaker
Erik Amundrud
MilliporeSigma
Sr. Manufacturing Manager
Erik Amundrud is the senior manager, manufacturing, with the viral vector CDMO team in Carlsbad, California. Erik has been in the biopharma industry for over 20 years and is accomplished in optimizing, scaling up, and manufacturing cell and gene therapies in a GMP environment. He is passionate about building high-performance production teams and improving process efficiency to support growing production capabilities.
Pharma and biopharma manufacturing
- Viral Vector Vaccine Manufacturing
Duration:1h
Language:English
Session 1:presented May 11, 2023
To continue reading please sign in or create an account.
Don't Have An Account?